NCI-H1703 Xenograft Model Service for NSCLC

The NCI-H1703 xenograft model, derived from a smoker with stage I lung squamous cell carcinoma, carries PDGFRα and FGFR1 amplifications together with DDR2 kinase mutations, offering a robust preclinical system for evaluating receptor tyrosine kinase inhibitors in LUSC. Alfa Cytology provides authenticated NCI-H1703 cell line-derived xenograft services with documented molecular profiling, enabling precise assessment of targeted agents against squamous NSCLC oncogenic drivers.

Overview of NCI-H1703 Xenograft Model for NSCLC

NCI-H1703 was established in 1987 from a stage I lung squamous cell carcinoma in a 54-year-old Caucasian male with a 50 pack-year smoking history. This epithelial cell line exhibits hallmark molecular alterations of smoking-associated LUSC, including amplification of the PDGFRα and FGFR1 genes and a mutation in the DDR2 kinase domain, rendering it selectively sensitive to dasatinib and other multi-kinase inhibitors. Its wild-type EGFR, KRAS, and ALK status further distinguishes it as a model representative of the approximately 25% of NSCLC cases driven by receptor tyrosine kinase amplifications rather than canonical driver mutations.

Fig 1. Intraperitoneal ZK53, a selective human ClpP activator, almost completely suppressed growth of NCI-H1703 xenografts (P=7.8×10^-8) and reduced tumor weight and Ki67 staining, while also shrinking autochthonous lung tumors in KrasG12D;Trp53fl/fl mice. (Zhou, Lin-Lin, et al., 2023)

When engrafted subcutaneously in immunodeficient mice, NCI-H1703 forms moderately aggressive tumors that retain squamous differentiation markers such as cytokeratins and p63. The model has been extensively utilized to validate FGFR1-directed therapies, including AZD4547, nintedanib, and ponatinib, as well as to explore DDR2-targeted strategies with dasatinib. Its predictable tumor kinetics and well-characterized drug response profile make it an essential platform for benchmarking novel agents in squamous NSCLC preclinical development.

Cell Line Information: NCI-H1703

The NCI-H1703 cell line was deposited by Dr. A. Gazdar and Dr. J. Minna and is distributed by ATCC. Key specifications pertinent to preclinical LUSC research are detailed below:

Our Services

Alfa Cytology constructs NCI-H1703 xenografts with verified PDGFRα and FGFR1 amplification status, offering study designs that range from single-agent tyrosine kinase inhibitor evaluation to combination regimens targeting parallel signaling axes, supported by comprehensive histopathological and molecular endpoint analysis.

Workflow of NCI-H1703 Xenograft Model Construction

NCI-H1703 xenograft construction follows a standardized protocol adapted for adherent epithelial cells with amplified receptor tyrosine kinase signaling, ensuring reproducible tumor formation and robust pharmacological readouts. The procedure comprises six sequential stages:

1. Cell Expansion and Molecular Verification: NCI-H1703 cells are propagated in RPMI-1640 with 10% FBS to log-phase growth. Each batch is authenticated by STR profiling, tested for mycoplasma, and confirmed for FGFR1 and PDGFRα amplification status prior to implantation.
2. Harvest and Matrigel Preparation: Adherent cultures are detached with trypsin-EDTA, washed, and counted. Cells are resuspended at 1 × 10⁷ cells/mL in a 1:1 mixture of serum-free RPMI-1640 and high-concentration Matrigel to preserve clonal architecture and promote stromal interaction.
3. Subcutaneous Implantation: A 100 µL suspension containing 1 × 10⁶ viable cells is injected subcutaneously into the flank of immunodeficient mice. Tumor nodules typically become palpable within 7–10 days post-injection.
4. Tumor Monitoring and Randomization: Tumor dimensions are measured twice weekly with digital calipers, and volume is calculated as (length × width²) / 2. Upon reaching 100–150 mm³, animals are randomized into treatment cohorts stratified by tumor volume and body weight.
5. Dosing and In-Life Assessments: Test compounds are administered according to the predefined dosing schedule. Tumor volumes and body weights are recorded at regular intervals. Optional blood collection supports pharmacokinetic and pharmacodynamic correlation.
6. Necropsy and Endpoint Analysis: At study termination, tumors are excised, weighed, and photographed. Tissues are fixed in 10% neutral buffered formalin for H&E and immunohistochemistry, with portions snap-frozen for genomic, transcriptomic, or proteomic analyses.

Fig 2. NCI-H1703 xenograft model construction workflow.

Case Study-NCI-H1703 Xenograft Model Development

In a preclinical program investigating a novel FGFR1-selective inhibitor, NCI-H1703 xenografts were established in athymic nude mice and dosed orally once daily for 21 days. The investigational compound produced dose-dependent tumor growth inhibition across multiple treatment arms, with the highest dose cohort demonstrating sustained suppression relative to vehicle-treated controls. Post-study immunohistochemistry revealed diminished phospho-FGFR1 staining and reduced Ki-67 proliferation indices in responder tumors, alongside increased cleaved caspase-3 expression indicative of apoptosis induction. These preclinical findings provided mechanistic validation and supported the compound's progression into extended combination studies with downstream pathway antagonists.

Why Choose Alfa Cytology?

Alfa Cytology combines molecular precision with operational excellence to deliver NCI-H1703 xenograft data that advance squamous NSCLC therapeutic development.

• Every NCI-H1703 batch is authenticated by STR profiling and confirmed for FGFR1 and PDGFRα amplification prior to study initiation.
• We offer flexible combination study designs pairing FGFR or DDR2 inhibitors with MEK, PI3K, or immunomodulatory agents.
• Tumor growth is monitored with electronic calipers and optional non-invasive imaging for continuous longitudinal assessment.
• All in vivo work is conducted in AAALAC-accredited facilities under IACUC-approved protocols with comprehensive veterinary oversight.
• Deliverables include detailed statistical reports, individual animal data, and publication-ready histopathology images with squamous marker staining.

Contact Us

If your LUSC drug discovery program requires a validated FGFR1-amplified preclinical model with documented DDR2 mutational status, contact Alfa Cytology today. Our preclinical team is prepared to design a customized NCI-H1703 xenograft program that aligns with your compound mechanism, target engagement strategy, and development timeline.

For research use only. Not intended for any clinical use.